This was the stock's second consecutive day of losses.
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
By Rick Winterson Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge. It has now established its global headquarters on Fan Pier in South ...
The stock's fall snapped a four-day winning streak.
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.
Hosted on MSN4d
FDA approves Vertex non-opioid pain drugThe FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback